DHSC Launches Industry Readiness Survey on Value Based Procurement

Key Takeaways

• DHSC seeks single response per MedTech firm.
• Survey deadline: 27 March, 10‑minute completion.
• VBP shifts focus from price to outcomes.
• Pilot evaluation ends early April; guidance due June.
• Suppliers must prove clinical and cost benefits.

Summary

The UK Department of Health and Social Care (DHSC) has launched an industry‑readiness survey on Value Based Procurement (VBP), targeting MedTech and health‑technology firms. The ten‑minute questionnaire seeks a single consolidated response per company and must be submitted by 27 March. VBP reorients NHS purchasing from price‑first to outcomes‑first, requiring evidence of clinical benefit, cost reduction, sustainability and supply continuity. Results will inform guidance slated for early June after a pilot evaluation in late March‑early April.

Pulse Analysis

Value Based Procurement marks a strategic pivot for the NHS, moving away from traditional cost‑centric contracts toward a model that ties payment to demonstrable health outcomes. Policymakers are motivated by rising healthcare expenditures and the need to align incentives with patient‑centered care, sustainability, and long‑term value. By embedding clinical effectiveness, reduced complications, and lifecycle costs into procurement criteria, VBP aims to foster a more innovative ecosystem where manufacturers compete on real‑world impact rather than headline price.

The DHSC’s newly released survey is a practical step to gauge industry preparedness for this transition. Designed with stakeholder input, the ten‑minute questionnaire asks firms to self‑assess capabilities such as data analytics, outcome measurement, and supply‑chain resilience. A single consolidated response per company streamlines data collection, while the 27 March deadline creates a tight feedback loop ahead of the pilot’s formal evaluation in late March and early April. The insights gathered will shape the forthcoming guidance, expected in early June, that will codify VBP requirements for broader NHS adoption.

For MedTech suppliers, the survey signals both a compliance checkpoint and a strategic opportunity. Companies that can substantiate clinical benefits, lower total cost of ownership, and robust sustainability metrics will be better positioned to win contracts under the new framework. This may accelerate investment in real‑world evidence generation, digital health platforms, and post‑market surveillance capabilities. Early engagement with DHSC’s survey also offers a channel to influence policy nuances, ensuring that implementation pathways reflect practical industry realities while driving the NHS toward higher‑value care.